{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:06:49Z","timestamp":1789142809342,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24282-3","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:48:18Z","timestamp":1763477298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and external validation of a pre-treatment nomogram for predicting drug-induced liver injury risk in tuberculosis patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Gang-Feng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"24282_CR1","volume-title":"WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Susceptible Tuberculosis Treatment","author":"WH Organization","year":"2022","unstructured":"Organization, W. H. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Susceptible Tuberculosis Treatment (World Health Organization, 2022)."},{"key":"24282_CR2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00210-023-02679-z","volume":"397","author":"HK Rana","year":"2024","unstructured":"Rana, H. K., Singh, A. K., Kumar, R. & Pandey, A. K. Antitubercular drugs: Possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity. Naunyn Schmiedebergs Arch. Pharmacol. 397, 1251\u20131273. https:\/\/doi.org\/10.1007\/s00210-023-02679-z (2024).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"24282_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/14740338.2024.2399074","volume":"23","author":"JH Lewis","year":"2024","unstructured":"Lewis, J. H., Korkmaz, S. Y., Rizk, C. A. & Copeland, M. J. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opin Drug Saf. 23, 1093\u20131107. https:\/\/doi.org\/10.1080\/14740338.2024.2399074 (2024).","journal-title":"Expert Opin Drug Saf."},{"key":"24282_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"EASL Clinical Practice Guidelines","year":"2019","unstructured":"EASL Clinical Practice Guidelines. Drug-induced liver injury. J. Hepatol. 70, 1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014 (2019).","journal-title":"J. Hepatol."},{"key":"24282_CR5","doi-asserted-by":"publisher","first-page":"1153815","DOI":"10.3389\/fphar.2023.1153815","volume":"14","author":"S Ji","year":"2023","unstructured":"Ji, S., Lu, B. & Pan, X. A nomogram model to predict the risk of drug-induced liver injury in patients receiving anti-tuberculosis treatment. Front. Pharmacol. 14, 1153815. https:\/\/doi.org\/10.3389\/fphar.2023.1153815 (2023).","journal-title":"Front. Pharmacol."},{"key":"24282_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen, J. J. et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit Care Med. 174, 935\u2013952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST (2006).","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"24282_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027810","volume":"6","author":"G Yimer","year":"2011","unstructured":"Yimer, G. et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 6, e27810. https:\/\/doi.org\/10.1371\/journal.pone.0027810 (2011).","journal-title":"PLoS ONE"},{"key":"24282_CR8","doi-asserted-by":"publisher","first-page":"1406454","DOI":"10.3389\/fphar.2024.1406454","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury. Front. Pharmacol. 15, 1406454. https:\/\/doi.org\/10.3389\/fphar.2024.1406454 (2024).","journal-title":"Front. Pharmacol."},{"key":"24282_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241346","volume":"15","author":"LK Gezahegn","year":"2020","unstructured":"Gezahegn, L. K., Argaw, E., Assefa, B., Geberesilassie, A. & Hagazi, M. Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study. PLoS ONE 15, e0241346. https:\/\/doi.org\/10.1371\/journal.pone.0241346 (2020).","journal-title":"PLoS ONE"},{"key":"24282_CR10","doi-asserted-by":"publisher","DOI":"10.2196\/29226","volume":"9","author":"T Zhong","year":"2021","unstructured":"Zhong, T. et al. Predicting antituberculosis drug-induced liver injury using an interpretable machine learning method: Model development and validation study. JMIR Med. Inform. 9, e29226. https:\/\/doi.org\/10.2196\/29226 (2021).","journal-title":"JMIR Med. Inform."},{"key":"24282_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/hmer.S290542","volume":"13","author":"Y Molla","year":"2021","unstructured":"Molla, Y., Wubetu, M. & Dessie, B. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med. 13, 1\u20138. https:\/\/doi.org\/10.2147\/hmer.S290542 (2021).","journal-title":"Hepat Med."},{"key":"24282_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/liv.14896","volume":"41","author":"F Jiang","year":"2021","unstructured":"Jiang, F. et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int. 41, 1565\u20131575. https:\/\/doi.org\/10.1111\/liv.14896 (2021).","journal-title":"Liver Int."},{"key":"24282_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2503848","author":"AA Mangoni","year":"2025","unstructured":"Mangoni, A. A., Woodman, R. J. & Jarmuzewska, E. A. Pharmacokinetic and pharmacodynamic alterations in older people: What we know so far. Expert Opin Drug Metab. Toxicol. https:\/\/doi.org\/10.1080\/17425255.2025.2503848 (2025).","journal-title":"Expert Opin Drug Metab. Toxicol."},{"key":"24282_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40264-023-01390-5","volume":"47","author":"EB Cohen","year":"2024","unstructured":"Cohen, E. B. et al. Drug-induced liver injury in the elderly: Consensus statements and recommendations from the IQ-DILI initiative. Drug Saf. 47, 301\u2013319. https:\/\/doi.org\/10.1007\/s40264-023-01390-5 (2024).","journal-title":"Drug Saf."},{"key":"24282_CR15","doi-asserted-by":"publisher","first-page":"1509785","DOI":"10.3389\/fchem.2025.1509785","volume":"13","author":"Q Zhu","year":"2025","unstructured":"Zhu, Q., Xie, X., Fang, L., Huang, C. & Li, J. Chronic alcohol intake disrupts cytochrome P450 enzyme activity in alcoholic fatty liver disease: Insights into metabolic alterations and therapeutic targets. Front. Chem. 13, 1509785. https:\/\/doi.org\/10.3389\/fchem.2025.1509785 (2025).","journal-title":"Front. Chem."},{"key":"24282_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02637-17","author":"WW Yew","year":"2018","unstructured":"Yew, W. W., Chang, K. C. & Chan, D. P. Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02637-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24282_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/10815589241299367","volume":"73","author":"M Celik","year":"2025","unstructured":"Celik, M. et al. Demographic, clinical and laboratory characteristics of extrapulmonary tuberculosis: Eight-year results of a multicenter retrospective study in Turkey. J. Investig. Med. 73, 206\u2013217. https:\/\/doi.org\/10.1177\/10815589241299367 (2025).","journal-title":"J. Investig. Med."},{"key":"24282_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040516","author":"I Meadows","year":"2025","unstructured":"Meadows, I. et al. N-acetylcysteine to reduce kidney and liver injury associated with drug-resistant tuberculosis treatment. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics17040516 (2025).","journal-title":"Pharmaceutics"},{"key":"24282_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030390","author":"M Villanueva-Paz","year":"2021","unstructured":"Villanueva-Paz, M. et al. Oxidative stress in drug-induced liver injury (DILI): From mechanisms to biomarkers for use in clinical practice. Antioxidants (Basel) https:\/\/doi.org\/10.3390\/antiox10030390 (2021).","journal-title":"Antioxidants (Basel)"},{"key":"24282_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.118535","volume":"1866","author":"D Galaris","year":"2019","unstructured":"Galaris, D., Barbouti, A. & Pantopoulos, K. Iron homeostasis and oxidative stress: An intimate relationship. Biochim. Biophys. Acta Mol. Cell Res. 1866, 118535. https:\/\/doi.org\/10.1016\/j.bbamcr.2019.118535 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"24282_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305855","volume":"19","author":"A Mahapatra","year":"2024","unstructured":"Mahapatra, A. et al. Effectiveness of food supplement on treatment outcomes and quality of life in pulmonary tuberculosis: Phased implementation approach. PLoS ONE 19, e0305855. https:\/\/doi.org\/10.1371\/journal.pone.0305855 (2024).","journal-title":"PLoS ONE"},{"key":"24282_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100423","volume":"31","author":"S Mandal","year":"2024","unstructured":"Mandal, S., Bhatia, V., Bhargava, A., Rijal, S. & Arinaminpathy, N. The potential impact on tuberculosis of interventions to reduce undernutrition in the WHO South-East Asian Region: A modelling analysis. Lancet Reg. Health Southeast Asia 31, 100423. https:\/\/doi.org\/10.1016\/j.lansea.2024.100423 (2024).","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"24282_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-008-9085-y","volume":"2","author":"HA Makhlouf","year":"2008","unstructured":"Makhlouf, H. A., Helmy, A., Fawzy, E., El-Attar, M. & Rashed, H. A. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol. Int. 2, 353\u2013360. https:\/\/doi.org\/10.1007\/s12072-008-9085-y (2008).","journal-title":"Hepatol. Int."},{"key":"24282_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.14218\/jcth.2022.00077","volume":"11","author":"D Huang","year":"2023","unstructured":"Huang, D. et al. Time of liver function abnormal identification on prediction of the risk of anti-tuberculosis-induced liver injury. J. Clin. Transl. Hepatol. 11, 425\u2013432. https:\/\/doi.org\/10.14218\/jcth.2022.00077 (2023).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"24282_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41512-021-00115-5","volume":"6","author":"AM Leeuwenberg","year":"2022","unstructured":"Leeuwenberg, A. M. et al. Performance of binary prediction models in high-correlation low-dimensional settings: A comparison of methods. Diagn Progn. Res. 6, 1. https:\/\/doi.org\/10.1186\/s41512-021-00115-5 (2022).","journal-title":"Diagn Progn. Res."},{"key":"24282_CR26","doi-asserted-by":"publisher","unstructured":"[Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)]. Zhonghua Jie He He Hu Xi Za Zhi 47, 1069\u20131090, https:\/\/doi.org\/10.3760\/cma.j.cn112147-20240614-00338 (2024).","DOI":"10.3760\/cma.j.cn112147-20240614-00338"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24282-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24282-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24282-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:48:20Z","timestamp":1763477300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24282-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24282"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24282-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest relevant to the content of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40631"}}